下一代流感疫苗的潜在全球健康影响与成本效果:一项模型分析
该模型分析基于世界卫生组织FluNet数据推断流感传播参数,在186个国家和地区模拟30年流感流行,评估当前季节性疫苗、提高效力/持续时间/广度的疫苗及通用流感疫苗的成本效果。下一代流感疫苗在许多国家于高于现有季节性疫苗通常支付价格的价位上具有成本效果,但低收入国家可能需要分层定价。
要点
- 下一代流感疫苗在许多国家于较高价位具有成本效果,低收入国家可能需要分层定价。
核心结论
- 下一代流感疫苗具有显著减少流感负担的潜力,并带来广泛的健康与经济收益。
- 下一代流感疫苗在高收入国家与中低收入国家之间的成本效果存在差异。
- 该研究为长期全球成本效果评价提供了框架,其发现可为下一代流感疫苗的开发与全球推广路径提供信息。
研究设计与样本
- 该研究为模型分析,在186个国家和地区预测下一代流感疫苗的健康与经济影响。
- 研究依据世界卫生组织FluNet数据,在按季节性流感时间与阳性率划分的区域推断当前流感传播参数。
- 研究预测30年流感流行,并考虑了人口学变化。
- 研究考虑的疫苗包括当前季节性疫苗、提高效力/持续时间/广度的疫苗以及按世界卫生组织首选产品特性定义的通用疫苗。
- 研究使用关键健康结局与成本的新估计值,评估不同接种情景的成本效果。
主要发现
- 在许多国家,下一代流感疫苗在高于现有季节性疫苗通常支付价格的价位上具有成本效果。
- 对改良疫苗而言,低收入国家可能需要分层定价才能具有成本效果。
关键数值与推荐
- 在许多国家,下一代流感疫苗在高于现有季节性疫苗通常支付价格的价位上具有成本效果。
- 对改良疫苗而言,低收入国家可能需要分层定价才能具有成本效果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 该研究受流感发病率及流感相关健康结局与成本准确数据可得性的限制。
- 该模型对接种覆盖率与实施方式作了简化假设。
- 该模型未考虑下一代流感疫苗的社会成本或预算影响。
- 下一代流感疫苗开发后与本模型所考虑疫苗类型的比较尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Next-generation influenza vaccines (NGIVs) are in development and have the potential to achieve substantial reductions in influenza burden, with resulting widespread health and economic benefits. The prices at which their market can be sustained and which vaccination strategies may maximise health impact and cost-effectiveness, particularly in low- and middle-income countries, are unknown, yet such an understanding could provide a valuable tool for vaccine development and investment decision-making at a national and global level. To address this evidence gap, we projected the health and economic impact of NGIVs in 186 countries and territories. METHODS AND FINDINGS: We inferred current influenza transmission parameters from World Health Organization (WHO) FluNet data in regions defined by their seasonal influenza timing and positivity, and projected 30 years of influenza epidemics, accounting for demographic changes. We considered vaccines including current seasonal vaccines, vaccines with increased efficacy, duration, and breadth of protection, and universal vaccines, defined in line with WHO Preferred Product Characteristics. We estimated cost-effectiveness of different vaccination scenarios using novel estimates of key health outcomes and costs. NGIVs have the potential to substantially reduce influenza burden: compared to no vaccination, vaccinating 50% of children aged under 18 annually prevented 1.3 (95% uncertainty range (UR): 1.2-1.5) billion infections using current vaccines, 2.6 (95% UR: 2.4-2.9) billion infections using vaccines with improved efficacy or breadth, and 3.0 (95% UR: 2.7-3.3) billion infections using universal vaccines. In many countries, NGIVs were cost-effective at higher prices than typically paid for existing seasonal vaccines. However, tiered prices may be necessary for improved vaccines to be cost-effective in lower income countries. This study is limited by the availability of accurate data on influenza incidence and influenza-associated health outcomes and costs. Furthermore, the model involves simplifying assumptions around vaccination coverage and administration, and does not account for societal costs or budget impact of NGIVs. How NGIVs will compare to the vaccine types considered in this model when developed is unknown. We conducted sensitivity analyses to investigate key model parameters. CONCLUSIONS: This study highlights the considerable potential health and economic benefits of NGIVs, but also the variation in cost-effectiveness between high-income and low- and middle-income countries. This work provides a framework for long-term global cost-effectiveness evaluations, and the findings can inform a pathway to developing NGIVs and rolling them out globally.
引用
- Goodfellow L, Procter SR, Koltai M, et al. The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis. PLoS Med. 2025. PMID: 40587557. doi:10.1371/journal.pmed.1004655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。